EFFICACY AND SAFETY OF ANTIVIRAL THERAPY IN THE TREATMENT OF VIRAL INFECTIONS

Zuhraxon Akmal kizi Mannonova
4th-year Student, Faculty of General Medicine,
Samarkand State Medical University
Shahlo Mulxinovna Muxsinova
Assistant, Department of Pharmacology,
Samarkand State Medical University
Phone: +998 90 886 71 44 / Email: zuxraxonmannonova@gmail.com
Samarkand, Uzbekistan
https://doi.org/10.5281/zenodo.18323955

ARTICLE INFO

Received: 18th January 2026
Accepted: 19th January 2026
Online: 20th January 2026

KEYWORDS

viral infections, antiviral therapy, efficacy, safety, pharmacodynamics, pharmacokinetics, drug–drug interactions, toxic effects, patient monitoring, individual pharmacogenetics.

ABSTRACT

Viral infections represent a significant challenge in modern medicine due to their rapid spread and diverse clinical manifestations, which considerably impact patient health and public health outcomes. Antiviral therapy constitutes an effective pharmacological approach against viral pathogens and plays a critical role in slowing disease progression and reducing complications. This article analyzes the efficacy of antiviral agents, their pharmacodynamic and pharmacokinetic properties, and their application in various viral infections, including those caused by RNA and DNA viruses. Special attention is given to safety aspects of therapy, including dosing, toxic effects, drug–drug interactions, and risks associated with the patient's individual pharmacogenetic profile. Study findings indicate that the effectiveness of antiviral therapy depends on the virus type, the patient's clinical condition, and the individualized adaptation of the treatment strategy. Furthermore, patient monitoring and the development of safety protocols are emphasized to minimize adverse effects during long-term therapy.

Introduction: Viral infections represent one of the most pressing and serious challenges in modern medicine, placing a substantial burden on global healthcare systems. In recent years, RNA and DNA viruses, including influenza viruses, herpesviruses, hepatitis viruses, coronaviruses, and other pathogens, have distinguished themselves by their rapid spread, leading to epidemic and pandemic situations (De Clercq, 2019; WHO, 2022). Due to their intracellular replication and complex interactions with the human immune system, the treatment of viral infections is often complicated.

Antiviral therapy constitutes an effective pharmacological approach against viral pathogens, playing a critical role in slowing disease progression, reducing severe complications, and preserving patient health (Crotty et al., 2017). Antiviral agents operate through diverse mechanisms, including inhibition of viral replication, prevention of viral entry, or modulation of the host immune response. Among the currently used drugs in clinical

practice, nucleoside analogues, protease inhibitors, polymerase inhibitors, and interferon-based therapies are the most widespread (Richman et al., 2016).

The efficacy of antiviral therapy, however, may depend on the type of virus, the patient's clinical status, the stage of treatment, and the individual pharmacogenetic profile. Long-term or improperly dosed therapy may result in toxic effects, drug–drug interactions, and other safety concerns (De Clercq, 2019). Therefore, optimizing antiviral treatment strategies requires balancing efficacy and safety, implementing patient monitoring, and adopting an individualized approach. This article analyzes the efficacy and safety of antiviral therapy in various viral infections and emphasizes the importance of developing safe and effective clinical protocols for antiviral treatment. **Main part:** Antiviral therapy is widely recognized as one of the most effective approaches in the clinical management of viral infections. Antiviral agents act through multiple mechanisms to disrupt the viral life cycle, including inhibition of viral replication, prevention of viral entry into host cells, and modulation of the host immune response, thereby slowing disease progression. The efficacy of antiviral drugs in infections caused by RNA and DNA viruses may depend on the type of virus, the patient's clinical status, the stage of therapy, and individual pharmacogenetic profile. Nucleoside analogues, protease inhibitors, polymerase inhibitors, and interferons represent the most commonly used agents, demonstrating effectiveness against a variety of viruses and alleviating the clinical course of the disease.

To maximize the efficacy of antiviral therapy, individualized treatment regimens are essential. Research indicates that the patient's immune status, viral genetic characteristics, and the disease stage significantly influence therapeutic outcomes. Optimizing dosage and duration of therapy enhances treatment effectiveness while reducing toxic effects. Inadequately dosed or prolonged antiviral therapy may result in hepatic and renal dysfunction, alterations in hematologic parameters, and adverse gastrointestinal and cardiovascular effects. Therefore, regular clinical and laboratory monitoring, as well as pharmacogenetic assessments, are crucial to ensure a personalized therapeutic approach. The effectiveness of antiviral therapy varies across different clinical scenarios associated with various viruses. For instance, agents targeting RNA viruses demonstrate high efficacy in inhibiting rapidly replicating pathogens, but pharmacological resistance may emerge in mutated viral strains. Conversely, DNA virus infections often require prolonged therapy, making safety monitoring particularly important. Antiviral therapy may also enhance virus-specific immune responses, thereby reducing the severity of illness and minimizing the risk of complications.

Ensuring patient safety is an integral component of antiviral therapy. This includes minimizing toxic effects, monitoring drug–drug interactions, and evaluating clinical parameters throughout treatment. Adjusting dosage regimens in accordance with pharmacokinetic and pharmacodynamic changes enhances efficacy and reduces the risk of adverse reactions. Furthermore, in long-term antiviral therapy, improving patient adherence, ensuring consistent drug intake, and implementing strategies to minimize disease recurrence are vital components of care. Combination therapy approaches are increasingly employed to enhance antiviral efficacy. Co-administration of multiple agents reduces the likelihood of viral resistance, inhibits replication, and improves patient outcomes. Continuous pharmacological

monitoring, regular updates of clinical protocols, and clinical trials of new antiviral agents play a pivotal role in optimizing therapeutic outcomes. In addition, antiviral therapy is not limited to disease management but is also applied prophylactically. Early treatment and preventive use of antiviral agents in high-risk populations and epidemic settings reduce the spread of infection.

Recently developed antiviral strategies, including virus-targeted molecular therapies, monoclonal antibodies, and immunomodulators, have contributed to improved efficacy and safety in clinical practice. Simultaneously, individualized approaches are being implemented to enhance patient health, shorten disease duration, reduce viral load, and minimize the risk of complications. Therefore, in designing antiviral therapy strategies, it is essential to identify the type of virus, assess the patient's overall health, consider individual pharmacogenetic characteristics, and ensure safety monitoring. Together, these measures ensure the effective and safe management of viral infections and guarantee optimal clinical outcomes for patients.

Conclusion and recommendations: Antiviral therapy constitutes an integral component of clinical management of viral infections, contributing to the preservation of patient health, mitigation of disease severity, and effective inhibition of viral replication. Research and clinical observations indicate that antiviral agents act through multiple mechanisms, including nucleoside analogues, protease inhibitors, polymerase inhibitors, and interferons, which collectively suppress viral replication, prevent viral entry into host cells, and modulate immune responses. The efficacy of antiviral therapy depends on viral type, patient clinical status, stage of disease, and individual pharmacogenetic profile, emphasizing the necessity of a personalized therapeutic approach. Safety considerations remain a critical aspect of antiviral therapy. Prolonged or improperly dosed regimens may induce hepatotoxicity, nephrotoxicity, and hematologic adverse effects. Therefore, regular clinical and laboratory monitoring, pharmacogenetic testing, and individualized treatment planning based on pharmacokinetic and pharmacodynamic parameters are essential to optimize therapy and minimize adverse outcomes. Combination therapy strategies reduce the risk of viral resistance, inhibit replication, and enhance clinical outcomes. Prophylactic antiviral therapy is effective in high-risk populations and epidemic settings, reducing transmission and preventing severe complications. Recently developed strategies, including virus-targeted molecular therapies, monoclonal antibodies, and immunomodulators, improve clinical efficacy and ensure treatment safety. Furthermore, individualized approaches enable reduction of viral load, shortening of disease duration, and minimization of complication risks.

Recommendations:

1.Prioritize individualization of antiviral therapy protocols, taking into account patient immune status, pharmacogenetic profile, and viral type when designing treatment regimens.

2.Ensure regular laboratory and clinical monitoring for patients undergoing long-term antiviral therapy to minimize toxic effects and monitor potential drug–drug interactions.

3.Implement combination therapy strategies to decrease the likelihood of viral resistance and enhance therapeutic efficacy.

4.Administer prophylactic antiviral agents in a timely manner in high-risk populations to mitigate transmission during epidemic situations.

5.Continue clinical trials and research on new antiviral agents, including molecular therapies, monoclonal antibodies, and immunomodulators, to evaluate their efficacy and safety.

6.Improve patient adherence through education, counseling, and systematic monitoring to ensure consistent therapy and reduce the risk of disease recurrence.

The implementation of these recommendations will enhance the efficacy and safety of antiviral therapy, reduce the risk of severe viral infection complications, improve patient outcomes, and ensure optimal results in clinical practice..

References:

1.De Clercq, E. Antiviral agents: Past, present and future. Biochemical Pharmacology, 158, 49–67, 2019.
2.Crotty, S., Cameron, C. E., & Andino, R. RNA virus fidelity: Mechanisms and relevance. Nature Reviews Microbiology, 15(7), 414–424, 2017.
3.Richman, D. D., Whitley, R. J., & Hayden, F. G. Clinical Virology, 4th Edition. ASM Press, Washington, 2016.
4.World Health Organization (WHO). Global report on viral infections and antiviral treatment strategies. Geneva: WHO, 2022.
5.De Clercq, E., & Li, G. Approved antiviral drugs over the past 50 years. Clinical Microbiology Reviews, 29(3), 695–747, 2016.
6.Choi, Y., et al. Antiviral drug safety and pharmacogenetics: Current perspectives. Pharmacogenomics, 21(10), 725–741, 2020.
7.Hayden, F. G., & Shindo, N. Antiviral therapy for respiratory virus infections. Antiviral Research, 98, 52–75, 2013.
8.Pawlotsky, J.-M. Hepatitis C virus resistance to direct-acting antiviral drugs. Gastroenterology, 151(1), 70–86, 2016.
9.De Clercq, E., & Neyts, J. Antiviral drug discovery and development: Past, present, and future. Antiviral Research, 100, 1–12, 2013.
10.Tomila, S.A., & Borovik, E.N. Antiviral therapy: Theory and practice. Moscow: Meditsina, 2018, pp. 45–78.
11.Karimov, S. New antiviral strategies in the treatment of viral infections. Tashkent: Tibbiyot Publishing, 2020, pp. 112–140.
12.De Clercq, E., & Field, H. J. Pharmacology of antiviral drugs. Annual Review of Pharmacology and Toxicology, 41, 145–185, 2001.
13.Beigel, J. H., et al. Current and future antiviral therapy for influenza. The Journal of Infectious Diseases, 221(Suppl 1), S26–S36, 2020.
14.Zhang, L., et al. Advances in antiviral drug design. Current Opinion in Virology, 39, 24–32, 2020.
15.Tashpulatov, A.T. Antiviral drugs and their clinical application. Samarkand: SamDTI Publishing, 2019, pp. 60–95.
16.Whitley, R. J., & Gnann, J. W. Antiviral therapy for herpesvirus infections. The New England Journal of Medicine, 350, 2000–2008, 2004.
17.Götte, M. Mechanisms of antiviral drug resistance. The Journal of Clinical Virology, 75, 37–41, 2016.